|
1
|
Ozaki T, Hillmann A, Lindner N, Blasius S
and Winkelmann W: Metastasis of chondrosarcoma. J Cancer Res Clin
Oncol. 122:625–628. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mirra J: Bone Tumors: Clinical,
radiologic, and pathologic correlations. Lea and Febiger;
Philadelphia, PA: 1989
|
|
3
|
Galoyan A: Neurochemistry of brain
neuroendocrine immune system: Signal molecules. Neurochem Res.
25:1343–1355. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Galoian K, Temple TH and Galoyan A:
Cytostatic effect of the hypothalamic cytokine PRP-1 is mediated by
mTOR and cMyc inhibition in high grade chondrosarcoma. Neurochem
Res. 36:812–818. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Galoian K, Temple HT and Galoyan A: mTORC1
inhibition and ECM-cell adhesion-independent drug resistance via
PI3K-AKT and PI3K-RAS-MAPK feedback loops. Tumour Biol. 33:885–890.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Galoian KA, Temple TH and Galoyan A:
Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in MDA
231 (ER-) breast carcinoma cell line. PRP-1 inhibits mesenchymal
tumors. Tumour Biol. 32:745–751. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Galoian KA, Guettouche T, Issac B, Qureshi
A and Temple HT: Regulation of onco and tumor suppressor MiRNAs by
mTORC1 inhibitor PRP-1 in human chondrosarcoma. Tumour Biol.
35:2335–2341. 2014. View Article : Google Scholar
|
|
8
|
Galoian K, Qureshi A, Wideroff G and
Temple HT: Restoration of desmosomal junction protein expression
and inhibition of H3K9-specific histone demethylase activity by
cytostatic proline-rich polypeptide-1 leads to suppression of
tumorigenic potential in human chondrosarcoma cells. Mol Clin
Oncol. 3:171–178. 2015. View Article : Google Scholar
|
|
9
|
Galoian K, Luo S, Qureshi A, Patel P,
Price R, Morse AS, Chailyan G, Abrahamyan S and Temple HT: Effect
of cytostatic proline rich polypeptide-1 on tumor suppressors of
inflammation pathway signaling in chondrosarcoma. Mol Clin Oncol.
5:618–624. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Galoian K, Qureshi A, D'Ippolito G,
Schiller PC, Molinari M, Johnstone AL, Brothers SP, Paz AC and
Temple HT: Epigenetic regulation of embryonic stem cell marker
miR302C in human chondrosarcoma as determinant of antiproliferative
activity of proline-rich polypeptide 1. Int J Oncol. 47:465–472.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu L, Wang L and Chen S: Exogenous or
endogenous Toll-like receptor ligands: Which is the MVP in
tumorigenesis? Cell Mol Life Sci. 69:935–949. 2012. View Article : Google Scholar
|
|
12
|
Rakoff-Nahoum S and Medzhitov R: Toll-like
receptors and cancer. Nat Rev Cancer. 9:57–63. 2009. View Article : Google Scholar
|
|
13
|
Joshi S, Kumar S, Choudhury A, Ponnusamy
MP and Batra SK: Altered Mucins (MUC) trafficking in benign and
malignant conditions. Oncotarget. 5:7272–7284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Blasius AL and Beutler B: Intracellular
toll-like receptors. Immunity. 32:305–315. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang B, Zhao J, Unkeless JC, Feng ZH and
Xiong H: TLR signaling by tumor and immune cells: A double-edged
sword. Oncogene. 27:218–224. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Apetoh L, Ghiringhelli F, Tesniere A,
Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E,
Saulnier P, et al: Toll-like receptor 4-dependent contribution of
the immune system to anticancer chemotherapy and radiotherapy. Nat
Med. 13:1050–1059. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Medzhitov R: Origin and physiological
roles of inflammation. Nature. 454:428–435. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seong SY and Matzinger P: Hydrophobicity:
An ancient damage-associated molecular pattern that initiates
innate immune responses. Nat Rev Immunol. 4:469–478. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hasan U, Chaffois C, Gaillard C, Saulnier
V, Merck E, Tancredi S, Guiet C, Brière F, Vlach J, Lebecque S, et
al: Human TLR10 is a functional receptor, expressed by B cells and
plasmacytoid dendritic cells, which activates gene transcription
through MyD88. J Immunol. 174:2942–2950. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lowe EL, Crother TR, Rabizadeh S, Hu B,
Wang H, Chen S, Shimada K, Wong MH, Michelsen KS and Arditi M:
Toll-like receptor 2 signaling protects mice from tumor development
in a mouse model of colitis-induced cancer. PLoS One. 5:e130272010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu L, Wang L and Chen S: Endogenous
toll-like receptor ligands and their biological significance. J
Cell Mol Med. 14:2592–2603. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tarang S, Kumar S and Batra SK: Mucins and
toll-like receptors: Kith and kin in infection and cancer. Cancer
Lett. 321:110–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kanzler H, Barrat FJ, Hessel EM and
Coffman RL: Therapeutic targeting of innate immunity with Toll-like
receptor agonists and antagonists. Nat Med. 13:552–559. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lakshminarayanan V, Thompson P, Wolfert
MA, Buskas T, Bradley JM, Pathangey LB, Madsen CS, Cohen PA,
Gendler SJ and Boons GJ: Immune recognition of tumor-associated
mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated
MUC1 tripartite vaccine. Proc Natl Acad Sci USA. 109:261–266. 2012.
View Article : Google Scholar :
|
|
25
|
Hollingsworth MA and Swanson BJ: Mucins in
cancer: Protection and control of the cell surface. Nat Rev Cancer.
4:45–60. 2004. View Article : Google Scholar
|
|
26
|
Remmers N, Anderson JM, Linde EM, DiMaio
DJ, Lazenby AJ, Wandall HH, Mandel U, Clausen H, Yu F and
Hollingsworth MA: Aberrant expression of mucin core proteins and
o-linked glycans associated with progression of pancreatic cancer.
Clin Cancer Res. 19:1981–1993. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sóñora C, Mazal D, Berois N, Buisine MP,
Ubillos L, Varangot M, Barrios E, Carzoglio J, Aubert JP and
Osinaga E: Immunohistochemical analysis of MUC5B apomucin
expression in breast cancer and non-malignant breast tissues. J
Histochem Cytochem. 54:289–299. 2006. View Article : Google Scholar
|
|
28
|
Kim YS, Gum J Jr and Brockhausen I: Mucin
glycoproteins in neoplasia. Glycoconj J. 13:693–707. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Turner MS, McKolanis JR, Ramanathan RK,
Whitcomb DC and Finn OJ: Mucins in gastrointestinal cancers. Cancer
Chemother Biol Response Modif. 21:259–274. 2003. View Article : Google Scholar
|
|
30
|
Berois N, Varangot M, Sóñora C,
Zarantonelli L, Pressa C, Laviña R, Rodríguez JL, Delgado F,
Porchet N, Aubert JP, et al: Detection of bone marrow-disseminated
breast cancer cells using an RT-PCR assay of MUC5B mRNA. Int J
Cancer. 103:550–555. 2003. View Article : Google Scholar
|
|
31
|
Moniaux N, Andrianifahanana M, Brand RE
and Batra SK: Multiple roles of mucins in pancreatic cancer, a
lethal and challenging malignancy. Br J Cancer. 91:1633–1638. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Andrianifahanana M, Moniaux N and Batra
SK: Regulation of mucin expression: Mechanistic aspects and
implications for cancer and inflammatory diseases. Biochim Biophys
Acta. 1765:189–222. 2006.PubMed/NCBI
|
|
33
|
Kufe DW: Mucins in cancer: Function,
prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Velcich A, Yang W, Heyer J, Fragale A,
Nicholas C, Viani S, Kucherlapati R, Lipkin M, Yang K and
Augenlicht L: Colorectal cancer in mice genetically deficient in
the mucin Muc2. Science. 295:1726–1729. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Van Seuningen I, Perrais M, Pigny P,
Porchet N and Aubert JP: Sequence of the 5′-flanking region and
promoter activity of the human mucin gene MUC5B in different
phenotypes of colon cancer cells. Biochem J. 348:675–686. 2000.
View Article : Google Scholar
|
|
36
|
Aziz MA, AlOtaibi M, AlAbdulrahman A,
AlDrees M and AlAbdulkarim I: Mucin family genes are downregulated
in colorectal cancer patients. J Carcinogene Mutagene.
S10:009:2014.
|
|
37
|
Wakata K, Tsuchiya T, Tomoshige K, Takagi
K, Yamasaki N, Matsumoto K, Miyazaki T, Nanashima A, Whitsett JA,
Maeda Y, et al: A favourable prognostic marker for EGFR mutant
non-small cell lung cancer: Immunohistochemical analysis of MUC5B.
BMJ Open. 5:e0083662015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Roy MG, Livraghi-Butrico A, Fletcher AA,
McElwee MM, Evans SE, Boerner RM, Alexander SN, Bellinghausen LK,
Song AS, Petrova YM, et al: Muc5b is required for airway defence.
Nature. 505:412–416. 2014. View Article : Google Scholar
|
|
39
|
Vincent A, Perrais M, Desseyn JL, Aubert
JP, Pigny P and Van Seuningen I: Epigenetic regulation (DNA
methylation, histone modifications) of the 11p15 mucin genes (MUC2,
MUC5AC, MUC5B, MUC6) in epithelial cancer cells. Oncogene.
26:6566–6576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Macha MA, Krishn SR, Jahan R, Banerjee K,
Batra SK and Jain M: Emerging potential of natural products for
targeting mucins for therapy against inflammation and cancer.
Cancer Treat Rev. 41:277–288. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Markossian KA, Gurvits BY and Galoyan AA:
Isolation and identification of novel peptides from secretory
granules of neuro-hypophysis. Neurochem Res. 16:221999.
|
|
42
|
Galoyan AA: Brain neurosecretory
cytokines: immune response and neuronal survival. Kluwer Academic
Plenum Publishers; New York: 2004, https://doi.org/10.1007/978-1-4419-8893-5.
View Article : Google Scholar
|
|
43
|
Abrahamyan SS, Davtyan TK, Khachatryan AR,
Tumasyan NV, Sahakyan IK, Harutyunyan HA, Chailyan SG and Galoyan
AA: Quantification of the hypothalamic proline rich polypeptide-1
in rat blood serum. Neurochem J. 8:38–43. 2014. View Article : Google Scholar
|
|
44
|
Yan YX, Boldt-Houle DM, Tillotson BP, Gee
MA, D'Eon BJ, Chang XJ, Olesen CE and Palmer MA: Cell-based
high-throughput screening assay system for monitoring G
protein-coupled receptor activation using beta-galactosidase enzyme
complementation technology. J Biomol Screen. 7:451–459. 2002.
View Article : Google Scholar
|
|
45
|
Frei AP, Moest H, Novy K and Wollscheid B:
Ligand-based receptor identification on living cells and tissues
using TRICEPS. Nat Protoc. 8:1321–1336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Slavoff SA and Saghatelian A: Discovering
ligand-receptor interactions. Nat Biotechnol. 30:959–961. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Omasits U, Ahrens CH, Müller S and
Wollscheid B: Protter: Interactive protein feature visualization
and integration with experimental proteomic data. Bioinformatics.
30:884–886. 2014. View Article : Google Scholar
|
|
48
|
Senapati S, Das S and Batra SK:
Mucin-interacting proteins: From function to therapeutics. Trends
Biochem Sci. 35:236–245. 2010. View Article : Google Scholar
|
|
49
|
Ozinsky A, Underhill DM, Fontenot JD,
Hajjar AM, Smith KD, Wilson CB, Schroeder L and Aderem A: The
repertoire for pattern recognition of pathogens by the innate
immune system is defined by cooperation between toll-like
receptors. Proc Natl Acad Sci USA. 97:13766–13771. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Janssens S and Beyaert R: Role of
Toll-like receptors in pathogen recognition. Clin Microbiol Rev.
16:637–646. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nilsen N, Nonstad U, Khan N, Knetter CF,
Akira S, Sundan A, Espevik T and Lien E: Lipopolysaccharide and
double-stranded RNA up-regulate toll-like receptor 2 independently
of myeloid differentiation factor 88. J Biol Chem. 279:39727–39735.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Seibert SA, Mex P, Köhler A, Kaufmann SH
and Mittrücker HW: TLR2-, TLR4- and Myd88-independent acquired
humoral and cellular immunity against Salmonella enterica serovar
Typhimurium. Immunol Lett. 127:126–134. 2010. View Article : Google Scholar
|
|
53
|
Jeung HC, Moon YW, Rha SY, Yoo NC, Roh JK,
Noh SH, Min JS, Kim BS and Chung HC: Phase III trial of adjuvant
5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin,
and polyad-enylic-polyuridylic acid (poly A:U) for locally advanced
gastric cancer after curative surgery: final results of 15-year
follow-up. Ann Oncol. 19:520–526. 2008. View Article : Google Scholar
|
|
54
|
Smits EL, Ponsaerts P, Berneman ZN and Van
Tendeloo VF: The use of TLR7 and TLR8 ligands for the enhancement
of cancer immunotherapy. Oncologist. 13:859–875. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Leonard JP, Link BK, Emmanouilides C,
Gregory SA, Weisdorf D, Andrey J, Hainsworth J, Sparano JA, Tsai
DE, Horning S, et al: Phase I trial of toll-like receptor 9 agonist
PF-3512676 with and following rituximab in patients with recurrent
indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res.
13:6168–6174. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mikulandra M, Pavelic J and Glavan TM:
Recent findings on the application of Toll- like receptors agonists
in cancer therapy. Curr Med Chem. 24:2011–2032. 2017. View Article : Google Scholar
|
|
57
|
Kaczanowska S, Joseph AM and Davila E: TLR
agonists: Our best frenemy in cancer immunotherapy. J Leukoc Biol.
93:847–863. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Rachagani S, Torres MP, Moniaux N and
Batra SK: Current status of mucins in the diagnosis and therapy of
cancer. Biofactors. 35:509–527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Planque N: Nuclear trafficking of secreted
factors and cell-surface receptors: New pathways to regulate cell
proliferation and differentiation, and involvement in cancers. Cell
Commun Signal. 4:72006. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Huhta H, Helminen O, Lehenkari PP, Saarnio
J, Karttunen TJ and Kauppila JH: Toll-like receptors 1, 2, 4 and 6
in esophageal epithelium, Barrett's esophagus, dysplasia and
adenocarcinoma. Oncotarget. 7:23658–23667. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Galoyan AA: Brain immune system signal
molecules in protection from aerobic and anaerobic infections.
Advances in Neurobiology. 6. Springer; 2012, View Article : Google Scholar
|
